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Abstract: HCoV-NL63 is a recently identified respiratory virus. Its pathogenesis has not 
been fully unraveled because an animal model is currently lacking. Here we examined 
whether rhesus macaques encounter HCoV-NL63 infections during life, by examining the 
levels of antibodies to HCoV-NL63 in time. The animals were followed for 7 up till 19 
years, and in three animals we observed a steep rise in antibodies during follow up, 
indicative of a natural infection with HCoV-NL63.  
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1. Introduction 
HCoV-NL63 was identified in 2004 in a child with bronchiolitis in The Netherlands [1], yet 
worldwide screenings revealed that the virus can be detected throughout the globe in children and 
adults with respiratory tract infections [2-8]. People acquire their first infection with HCoV-NL63 
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early in life [9], and during this first infection the chance to develop larynchotracheabronchitis (croup) 
is high [10]. With increasing age people experience repeated infections (unpublished findings LvdH), 
and in case of underlying disease an HCoV-NL63 infection can require hospitalization. On the whole 
we can say that within a few years a vast amount of data on this new virus has become available, 
except that the pathogenesis of HCoV-NL63 remains unknown. The lacking of an animal model 
system is the problem. In addition, an animal model system is needed to fulfill the Koch’s postulates 
and link infection to a disease.  
To date, only a limited number of primary or immortalized cells from either human or non-human 
primate origin support propagation of HCoV-NL63 [1,11-13]. The first HCoV-NL63 isolate that was 
cultured was propagated on tertiary monkey kidney cells of a cynomolgus monkey (latin: Macaca 
fascicularis) and subsequently passaged to LLC-MK2 cells, a cell line derived from the kidney of a 
rhesus macaque (latin: Macaca mulatta). It is of interest to investigate whether rhesus macaques can be 
infected by HCoV-NL63. This can either be investigated by direct inoculation of Rhesus Macaque 
with HCoV-NL63. Alternatively, one can establish whether rhesus macaques that are in close contact 
to humans have experienced a natural HCoV-NL63 infection by investigating the NL63-directed 
antibody titers in time. 
2. Results and Discussion 
A sudden rise in coronavirus antibody titers is a strong indication for a coronavirus infection. We 
have shown this for children who acquire their first HCoV-NL63 infection during their first years of 
life [9]. At later ages repeated infections with human coronaviruses can occur [14], depending on the 
levels of protective antibodies. Protective antibodies peak shortly after infection and gradually 
decrease during the following years, with accompanying susceptibility to a reinfection with time. In 
the current study we use the kinetics of the antibody response to HCoV-NL63 to determine whether 
rhesus macaques encounter natural infections with HCoV-NL63, or related coronaviruses. The 
serological assays were performed with the N-protein of HCoV-NL63 which is an immunodominant 
protein, although there is some homology with the N-protein of the closest relative of HCoV-NL63, 
HCoV-229E. To ascertain the most specificity, the C-terminal region (amino acids 215 to 377) of the 
protein – which has the most difference between NL63-N and 229E-N - was used. In addition 
competition experiments with homologous and heterologous proteins were included in each 
experiment to ascertain the specificity of an antibody response. 
The first indication of infections with HCoV-NL63-like viruses in rhesus macaques was found 
when we tested 32 serum samples of 32 monkeys (Table 1 and Figure 1). Five samples showed high 
levels of antibodies to the HCoV-NL63 protein. The same samples did not have elevated levels of 
antibodies to HCoV-229E, indicative that the response was specific (data not shown). Furthermore, 
competition experiments with the NL63-protein and the 229E-protein revealed that only the 
homologous protein could compete with binding to the NL63-protein on the ELISA plate (data not 
shown), suggesting that the antibodies are directed to an HCoV-NL63-like virus. Viruses 2009, 1                                       
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Table 1. Demographic characteristics of the Rhesus macaques included in HCoV-NL63 
antibody analysis. 
Rhesus Macaque ID  Sampling date  Date of birth  Genetic origin 
1 17-4-2008  26-3-1983  India 
2 24-4-2008  11-12-2000  India 
3 29-9-2008  4-5-1982  India 
4 29-9-2008  6-7-1983  India 
5 29-9-2008  16-10-1983  India 
6 6-10-2008  1-1-1996  Burma 
7 6-10-2008  9-8-1996  Burma 
8 6-10-2008  12-4-1989  Burma 
9 20-10-2008  6-4-2001  India 
10 27-10-2008  7-5-1995  Burma 
11 15-8-2007  7-1-1995  China 
12 15-8-2007  14-4-1995  China 
13 17-4-2007  20-9-1994  China 
14 17-4-2007  16-6-1994  China 
15 3-4-2008  6-8-1980  India 
16 10-4-2008  24-4-2000  India 
17 10-4-2008  1-5-2000  India 
18 10-4-2008  20-5-1995  Burma 
19 14-4-2008  3-12-1988  Burma 
20 14-4-2008  31-12-1988  Burma 
21 27-10-2008  12-1-1997  Burma 
22 27-10-2008  26-1-1997  Burma 
23 12-1-2009  4-1-1996  India 
24 12-1-2009  11-3-1996  India 
25 5-1-2009  11-3-2000  India 
26 29-12-2008  9-4-2001  India 
27 29-12-2008  13-3-2000  India 
28 13-1-2009  26-9-1995  Burma 
29 24-8-2000  5-2-1995  China 
30 30-1-2003  24-4-1995  China 
31 8-5-2006  27-12-1994  China 
32 4-2-2002  23-3-1995  China 
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Figure 1. Antibody levels to HCoV-NL63. On the X-axis the Rhesus Macaque ID is 
indicated. On the Y-axis relative luminescence signal (RLU) in an ELISA detecting 
antibodies to the C-terminal nucleocapsid protein is shown. Rhesus macaques of which 
longitudinally collected serum samples were analyzed are indicated with a “*”. 
 
 
Longitudinal serum samples were available of three rhesus macaques with the highest antibody 
levels to HCoV-NL63 (numbers 5, 10 and 17). These monkeys had been sampled on a regular basis, 
with on average one serum sample every one or two years. Sampling started when the macaques were 
already a few years old, except for one which was followed from 6 months of age. In all three animals 
a sudden rise in antibody titers was noticed (Figure 2, panel A, B and C). Rhesus macaque number 5 
was followed from 1989 (starting at the age of 6 years) with high levels of NL63-directed antibodies. 
A strong peak was observed in 2003, indicating that the animal experienced an additional HCoV-NL63 
infection (at 20 years of age). Animal number 10 started with low titers to HCoV-NL63 (age 2 years) 
but after some years very high titers to HCoV-NL63 were visible (age 8 years). Unexpectedly, these 
high antibody levels remained for the complete follow-up period (last sample collected at the age of 
13). This is suggesting that the adaptive immune response to HCoV-NL63 is constantly activated, and 
one could speculate that this animal is experiencing a chronic HCoV-NL63 infection. Unfortunately, 
additional samples like throat swabs or faeces to test for chronic infections were not available. The 
third animal (number 17) was followed from early age on, starting with low levels of NL63-antibodies. 
Between the years 2003/2004 a steep rise in antibody levels was noted, whereas a second rise occurred 
after the winter of 2006/2007 (at 4 years and almost 7 years of age respectively). The animals were all 
checked for antibodies to HCoV-229E, but for none of the three monkeys reactivity was detected 
(Figure 2). This is in accordance with the first screening of the animals, which already showed low 
levels of HCoV-229E antibodies in these animals. Viruses 2009, 1                                       
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Figure 2. Serological response to HCoV-NL63 and HCoV-229E in time. Reactivity to the 
C-terminal nucleocapsid protein of HCoV-NL63 is shown as closed circles (continuous 
line), to the HCoV-229E C-terminal nucleocapsid protein closed squares (dashed line). 
(a) Rhesus Macaque 5; (b) Rhesus Macaque 10; (c) Rhesus Macaque 17. The X-axis 
displays the age in years of the Rhesus Macaque during follow up, the Y-axis the relative 
luminescence signal (RLU) in the two C-terminal nucleocapsid protein antibody ELISAs. 
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Figure 3. Immunofluorescence detection of HCoV-NL63 in infected LLC-MK2 cells. 
Reactivity of rhesus macaque number 10 sera towards HCoV-NL63 infected (HCoV-NL63 
positive) and non-infected (control) LLC-MK2 cells, at the age of 6 (preseroconversion) 
and 8 (postseroconversion) years. The images represent the cell nucleus (blue) and rhesus 
macaque antibodies (green) signals. 
 
 
To confirm our findings we determined whether the post-seroconversion samples also react with 
whole virus by performing an immunofluorescence assay with HCoV-NL63 infected cells. In all cases 
with low HCoV-NL63 antibodies we saw no reactivity with the infected cells. Whereas all samples 
obtained after seroconversion showed clear reactivity with whole virus (shown for animal number 10 
in Figure 3). 
With the assay used we cannot obtain evidence that it were HCoV-NL63 infections that these 
monkeys have encountered. However, one can conclude that it were infections with HCoV-NL63, or a 
virus which is serologically closely related. It can never be excluded that there is a coronavirus 
infecting these rhesus monkeys that is closely related to HCoV-NL63 (but has not been identified yet). 
Sampling of the respiratory tract on a regular basis throughout the years and eventually identify the 
pathogen that is eliciting the antibody response can answer this question, but is not an easy task. To 
our opinion the most likely explanation would be that natural infection with HCoV-NL63 occurs. The 
macaques described in this study live in a closed system with close contacts to humans (feeding, 
cleaning of cages, etc.). Through this contact they can encounter the virus as infections of humans with 
HCoV-NL63 occurs frequently in winter seasons [10]. As the cells of this monkey species are Viruses 2009, 1                                       
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susceptible to infection (LLC-MK2 cells, a kidney epithelial cell line) it is very likely that in vivo 
infections can occur as well. 
The animals of our study were clinically examined on a routine yearly basis for colony health 
surveillance, but subclinical infections with coronaviruses will go unnoticed during this check up and 
in the periods between the examinations. Thus it can not be determined whether the seroconversion or 
reconversion to HCoV-NL63 was accompanied with minor clinical signs. Future studies should be 
designed to investigate viral infection with human viruses and the accompanying clinical signs to 
further unravel this subject. Here we show that it is not necessary to sacrifice monkeys by experimental 
infecting. A well-designed follow up through the years with serum and respiratory samples collected 
on a regular basis would be sufficient to unravel the potential of the human respiratory viruses to infect 
rhesus macaques. Once a cohort has set up and samples have been collected for a few years, all newly 
identified respiratory viruses can be screened with the appropriate serological assays, and infection 
related to clinical symptoms. 
Natural infections of rhesus macaques with viruses that are known to be of human origin are not 
unusual. It has been described that smallpox, measles, rubella or parainfluenzavirus 1 and 2 cause 
natural infection of Rhesus macaques and the closely related cynomolgus macaques [15,16]. 
Furthermore, experimental infection with several viruses showed that the animals are susceptible to 
various human respiratory viruses like respiratory syncytial virus and SARS coronavirus [17,18]. With 
the knowledge that natural infection of HCoV-NL63 is likely to occur, one should keep in mind that 
this has implications for animal model experiments. In case rhesus macaques are experimentally 
infected with HCoV-NL63 this might be a reinfection, in case the animal has encountered the virus 
previously, or the first infection, in case the animal is still young and was not naturally infected 
through human contact. The clinical signs during the first infection might be of a more severe nature in 
comparison with a recurrent infection. This should be taken into account in case a study is conducted 
to reveal the pathogenesis of the virus in an animal model system. 
3. Experimental Section 
Serum of Rhesus Macaque monkeys 
Cross-sectional and longitudinal serum specimens were collected from Rhesus macaques with an 
Indian, Burmese or Chinese genetic background. The Rhesus macaques were either imported or born 
in The Netherlands in one of the breeding colonies. The animals have not been isolated but remained 
in a breeding colony and were not used for immunization with antigens or adjuvant, or any other study. 
All serum specimens were stored at -80
oC and heat-inactivated at 56
oC for 30 minutes prior to 
analysis. 
Generation and expression of recombinant HCoV-NL63 and HCoV-229E carboxyl-terminal 
nucleocapsid proteins 
The generation of the plasmid construct was performed as described [9]. For HCoV-NL63 the 
following primer combination was used 5’ NL63_N5_CT (5’ – CACCAAACCTAATAAGCCTCT 
TTCTCAAC – 3’) and 3' NL63_Nexp (5’ – TTAATGCAAAACCTCGTTGAC – 3’), whereas for Viruses 2009, 1                                       
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HCoV-229E the primer combination 5’ 229E_5N_CT (5’ – CACCCCTTCTCGTAATCAGAGTCCT 
– 3’) and 3' 229E_Nexp (5’ – TTAGTTTACTTCATCAATTAT – 3’) was used. The generated 
pET100_NL63_CT and pET100_229E_CT plasmids were sequenced and shown to be 100% identical 
to the virus reference sequences of HCoV-NL63 (Amsterdam-01) and HCoV-229E (Inf-1), 
respectively. Subsequent expression and purification of the HCoV-NL63 and HCoV-229E 
recombinant carboxyl-terminal nucleocapsid proteins was performed as previously described [9]. 
Carboxyl-terminal nucleocapsid ELISA 
Ninety-six-well ELISA plates (Greiner Bio-one) were coated overnight at 4
oC with 3 μg/ml of 
expressed recombinant C-terminal N protein of HCoV-NL63 or HCoV-229E. The proteins were 
diluted in 0.1 M carbonate buffer pH 9.6. Unspecific binding sites were blocked with PBS + 0.1% 
Tween20 (PBST) supplemented with 5% skim milk (Fluka) for one hour at room temperature (RT). 
Longitudinal and cross-sectional sera were diluted 1:200, in PBST containing 1% skim milk and 
incubated on the plate for 2 hours at RT. After washing, Alkaline Phosphatase conjugated anti-monkey 
IgG antibody (Sigma Aldrich) diluted (1:40,000) in 1% skim milk PBST was added. Following one 
hour at RT the plates were washed and signal was developed with 50 μl of Lumi-Phos Plus (Lumigen). 
Measurements were done with a Glomax
TM 96 Plate Luminometer (Promega). All sera were tested in 
duplicate. 
Carboxyl-terminal nucleocapsid competition ELISA  
Rhesus Macaque sera were diluted (1:200) in PBST containing 1% skim milk and twofold serial 
dilutions ranging from 50 to 0 μg/ml of either expressed recombinant C-terminal N protein of HCoV-
NL63, N protein of HCoV-229E or LacZ protein and incubated for 1 hour at RT. Prior to incubation, 
the mixtures were briefly homogenized by vortexing. No centrifugation was performed. Following the 
pre-incubations the samples were measured by HCoV-NL63 or HCoV-229E ELISA, as described 
above. 
 
Immunofluorescence on HCoV-NL63 infected cells 
 
LLC-MK2 cells were seeded on coverslips in 12-well plates at a density of 0.32  106 cells / well 
and cultured at 37 °C with 5% CO2 in minimal essential medium (MEM; 2 parts Hanks’ MEM and 1 
part Earle’s MEM) supplemented with 3% heat-inactivated fetal calf serum (PAA Laboratories), 
penicillin (100 U/ml), and streptomycin (100 g/ml). Cells were infected with HCoV-NL63 at a 
multiplicity of infection of 0.007 and incubated at 37 °C with 5% CO2. After 4 days cells were fixated 
with 3.7% PFA in PBS for 30 minutes at room temperature (RT). The unspecific binding sites were 
blocked overnight at 4 °C with incubation buffer (2 % BSA (Sigma Aldrich) in PBS with 0.1% 
saponin and 50 mM ammonium chloride). For detection of HCoV-NL63 proteins cells were double 
stained for 1 hour at RT in incubation buffer with rabbit derived anti-S1-NL63 sera (1:200) and Rhesus 
macaque sera (1:100) as primary antibodies. Donkey derived, Dylight 649 labeled, anti-rabbit IgG 
(H+L) and donkey derived, Dylight 594 labeled, anti-human IgG (H+L) (1:200) (Jackson 
immunoresearch) were applied as secondary antibodies for 1 hour at RT in incubation buffer, followed Viruses 2009, 1                                       
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by nuclear DNA staining with Hoechst 33528. Fluorescent images were acquired on a Leica TCS SP2 
AOBS spectral confocal microscope with a 63x HCX PL APO 1.32 oil objective. 
4. Conclusions  
In the early days of human coronavirus identification (the 1960s) it was possible to experimentally 
infect volunteers with the viruses which were isolated from persons with common colds. Nowadays, 
with the recent epidemic of SARS-CoV, it is very difficult to attract volunteers for such studies. Not 
only has the public become aware of the potential dangers of a coronavirus infection, the recently 
identified viruses (HCoV-NL63 and HCoV-HKU1) have been isolated from children or adults with 
severe lower respiratory tract infection, and not simple common colds. Consequently, the only 
possibility to connect the recently identified coronaviruses to a certain disease is via associations with 
disease or animal experiments. To date no animal model system has been described for HCoV-NL63. 
Although all signs suggest that Rhesus macaques might be a good model system – since cells of 
Rhesus macaques can be in vitro infected by HCoV-NL63 – nobody has reported infection of these 
animals yet. We show here that there are clear signs that Rhesus macaques acquire natural infections 
with HCoV-NL63, or a serologically very closely related coronavirus. In future animal experiments to 
be carried out with Rhesus macaques the history of an animal should be known to determine whether 
the experimental infection occurs in an HCoV-NL63 naïve animal or an animal that has encountered 
the virus during life, as clinical symptoms might differ greatly in first or recurrent infection. 
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